高盛:重申敏實(0425.HK)“買入”評級 目標價33.5港元
高盛發表研究報告表示,敏實(0425.HK)將受惠於訂單改善、海外業務擴張及電池盒業務蓬勃發展,重申其“買入”評級,12個月的目標價為33.5港元。
高盛預測,自7月起,敏實的收入將可按年錄得雙位數升幅,主於受惠於市佔率提升、與內地國際品牌聯營公司的良好關係以及中國生產基地的成本具競爭力等。
隨着乘用車市場銷量跌幅收窄,高盛更新了敏實的報告,預測公司本地收入會較上半年按年下跌8%,於第三季顯著改善,主要因為本地乘用車的產量跌幅從上半年的16%收窄至第三季的6%,而日系/歐系及豪華車品牌持續跑贏同業亦使公司得益。
高盛估計,敏實第四季的訂單表現將可改善,尤其在農曆年前,代理透露10-11月市場需求恢復。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.